XML 24 R13.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Collaboration and Licensing Revenue | 6 Months Ended
--- | ---
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Collaboration and Licensing Revenue | Collaboration and Licensing Revenue The Company generates revenue through contractual agreements with collaborators (known as exclusive channel collaborations, "ECC" or "ECCs") and licensing agreements whereby the collaborators or the licensees obtain exclusive access to the Company's proprietary technologies for use in the research, development and commercialization of products and/or treatments in a contractually specified field of use. Upfront and milestone payments are typically deferred and recognized over the expected life of the Company's technology platform using a straight-line approach. The Company recognizes the reimbursement payments received for research and development services in the period in which the services are performed and collection is reasonably assured. The following tables summarize the amounts recorded as revenue in the consolidated statements of operations for each significant counterparty to a collaboration or licensing agreement for the three and six months ended June 30, 2017 and 2016.
| Three Months Ended June 30, 2017
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 4,842 |  |  | $ | 5,122 |  |  | $ | 9,964 |
Oragenics, Inc. | 261 |  |  | 214 |  |  | 475 |
Fibrocell Science, Inc. | 605 |  |  | 1,348 |  |  | 1,953 |
Genopaver, LLC | 68 |  |  | 1,445 |  |  | 1,513 |
S & I Ophthalmic, LLC | — |  |  | 72 |  |  | 72 |
OvaXon, LLC | — |  |  | 880 |  |  | 880 |
Intrexon Energy Partners, LLC | 625 |  |  | 1,295 |  |  | 1,920 |
Persea Bio, LLC | 125 |  |  | 141 |  |  | 266 |
Ares Trading S.A. | 1,597 |  |  | 1,206 |  |  | 2,803 |
Intrexon Energy Partners II, LLC | 500 |  |  | 456 |  |  | 956 |
Intrexon T1D Partners, LLC | 272 |  |  | 1,016 |  |  | 1,288 |
Harvest start-up entities (1) | 606 |  |  | 3,846 |  |  | 4,452 |
Other | 923 |  |  | 699 |  |  | 1,622 |
Total | $ | 10,424 |  |  | $ | 17,740 |  |  | $ | 28,164 |
(1) | For the three months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
| Three Months Ended June 30, 2016
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 922 |  |  | $ | 6,048 |  |  | $ | 6,970 |
Oragenics, Inc. | 261 |  |  | 246 |  |  | 507 |
Fibrocell Science, Inc. | 605 |  |  | 789 |  |  | 1,394 |
Genopaver, LLC | 68 |  |  | 1,569 |  |  | 1,637 |
S & I Ophthalmic, LLC | — |  |  | 2,358 |  |  | 2,358 |
OvaXon, LLC | — |  |  | 808 |  |  | 808 |
Intrexon Energy Partners, LLC | 625 |  |  | 3,587 |  |  | 4,212 |
Persea Bio, LLC | 125 |  |  | 206 |  |  | 331 |
Ares Trading S.A. | 1,597 |  |  | 621 |  |  | 2,218 |
Intrexon Energy Partners II, LLC | 500 |  |  | 394 |  |  | 894 |
Intrexon T1D Partners, LLC | 278 |  |  | 32 |  |  | 310 |
Harvest start-up entities (1) | 305 |  |  | 634 |  |  | 939 |
Other | 2,769 |  |  | 2,134 |  |  | 4,903 |
Total | $ | 8,055 |  |  | $ | 19,426 |  |  | $ | 27,481 |
(1) | For the three months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.
| Six Months Ended June 30, 2017
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 9,684 |  |  | $ | 11,265 |  |  | $ | 20,949 |
Oragenics, Inc. | 524 |  |  | 520 |  |  | 1,044 |
Fibrocell Science, Inc. | 1,210 |  |  | 2,482 |  |  | 3,692 |
Genopaver, LLC | 137 |  |  | 3,056 |  |  | 3,193 |
S & I Ophthalmic, LLC | — |  |  | 375 |  |  | 375 |
OvaXon, LLC | — |  |  | 1,704 |  |  | 1,704 |
Intrexon Energy Partners, LLC | 1,250 |  |  | 5,756 |  |  | 7,006 |
Persea Bio, LLC | 250 |  |  | 305 |  |  | 555 |
Ares Trading S.A. | 3,194 |  |  | 2,924 |  |  | 6,118 |
Intrexon Energy Partners II, LLC | 1,000 |  |  | 1,105 |  |  | 2,105 |
Intrexon T1D Partners, LLC | 536 |  |  | 1,884 |  |  | 2,420 |
Harvest start-up entities (1) | 1,207 |  |  | 6,608 |  |  | 7,815 |
Other | 2,756 |  |  | 1,497 |  |  | 4,253 |
Total | $ | 21,748 |  |  | $ | 39,481 |  |  | $ | 61,229 |
(1) | For the six months ended June 30, 2017, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.
| Six Months Ended June 30, 2016
| Revenue Recognized From |  | Total
| Upfront and Milestone Payments |  | Research and Development Services |
ZIOPHARM Oncology, Inc. | $ | 1,844 |  |  | $ | 12,107 |  |  | $ | 13,951 |
Oragenics, Inc. | 524 |  |  | 789 |  |  | 1,313 |
Fibrocell Science, Inc. | 1,210 |  |  | 2,041 |  |  | 3,251 |
Genopaver, LLC | 137 |  |  | 3,078 |  |  | 3,215 |
S & I Ophthalmic, LLC | — |  |  | 3,544 |  |  | 3,544 |
OvaXon, LLC | — |  |  | 1,502 |  |  | 1,502 |
Intrexon Energy Partners, LLC | 1,250 |  |  | 6,950 |  |  | 8,200 |
Persea Bio, LLC | 250 |  |  | 405 |  |  | 655 |
Ares Trading S.A. | 3,194 |  |  | 1,429 |  |  | 4,623 |
Intrexon Energy Partners II, LLC | 1,000 |  |  | 444 |  |  | 1,444 |
Intrexon T1D Partners, LLC | 278 |  |  | 32 |  |  | 310 |
Harvest start-up entities (1) | 351 |  |  | 1,022 |  |  | 1,373 |
Other | 3,789 |  |  | 4,384 |  |  | 8,173 |
Total | $ | 13,827 |  |  | $ | 37,727 |  |  | $ | 51,554 |
(1) | For the six months ended June 30, 2016, revenue recognized from collaborations with Harvest start-up entities include Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; and Relieve Genetics, Inc.
There have been no significant changes to arrangements with our collaborators and licensees in the six months ended June 30, 2017. See Note 5 in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 for additional details of the Company's existing collaboration and licensing agreements. Deferred Revenue Deferred revenue primarily consists of consideration received for upfront and milestone payments in connection with the Company's collaborations and licensing agreements, prepayments for research and development services performed for collaborators and licensees, and prepayments for product and service revenues. Deferred revenue consists of the following:
| June 30, 2017 |  | December 31, 2016
Upfront and milestone payments | $ | 278,262 |  |  | $ | 297,867 |
Prepaid research and development services | 2,502 |  |  | 6,015 |
Prepaid product and service revenues | 4,550 |  |  | 5,554 |
Other | 4 |  |  | 706 |
Total | $ | 285,318 |  |  | $ | 310,142 |
Current portion of deferred revenue | $ | 47,662 |  |  | $ | 53,364 |
Long-term portion of deferred revenue | 237,656 |  |  | 256,778 |
Total | $ | 285,318 |  |  | $ | 310,142 |
The following table summarizes the remaining balance of deferred revenue associated with upfront and milestone payments for each significant collaboration and licensing agreement.
| June 30, 2017 |  | December 31, 2016
ZIOPHARM Oncology, Inc. | $ | 129,125 |  |  | $ | 138,809 |
Oragenics, Inc. | 7,242 |  |  | 7,766 |
Fibrocell Science, Inc. | 17,816 |  |  | 19,026 |
Genopaver, LLC | 1,840 |  |  | 1,977 |
Intrexon Energy Partners, LLC | 16,875 |  |  | 18,125 |
Persea Bio, LLC | 3,750 |  |  | 4,000 |
Ares Trading S.A. | 43,984 |  |  | 47,178 |
Intrexon Energy Partners II, LLC | 14,833 |  |  | 15,833 |
Intrexon T1D Partners, LLC | 8,678 |  |  | 8,653 |
Harvest start-up entities (1) | 19,400 |  |  | 20,208 |
Other | 14,719 |  |  | 16,292 |
Total | $ | 278,262 |  |  | $ | 297,867 |
(1) | As of June 30, 2017 and December 31, 2016, the balance of deferred revenue for collaborations with Harvest start-up entities includes Thrive Agrobiotics, Inc.; Exotech Bio, Inc.; Relieve Genetics, Inc.; AD Skincare, Inc.; Genten Therapeutics, Inc.; and CRS Bio, Inc.

X
- Definition The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -URI http://asc.fasb.org/topic&trid=5833765 + Details
Name: | us-gaap_CollaborativeArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration